8-K: Avid Bioservices Announces $160 Million Convertible Note Offering to Refinance 2026 Debt

Avid Bioservices plans to raise $160 million through a private placement of convertible notes to repurchase and refinance its existing 2026 debt.

Summary

• Avid Bioservices intends to offer $160 million in Convertible Senior Notes due 2029 through a private placement.
• The company plans to use the proceeds to repurchase a portion of its 2026 Exchangeable Senior Notes and repay any remaining balance.
• The 2029 Notes will bear interest payable semi-annually and can be converted into cash, common stock, or a combination of both at the company's discretion.
• The initial conversion rate is set at 101.1250 shares per $1,000 principal amount, equivalent to a conversion price of approximately $9.89 per share.
• The offering is expected to close around March 12, 2024, subject to customary closing conditions.
• The 2026 Notes were accelerated and became due on February 29, 2024, prompting this refinancing effort.
• The company's third quarter revenue was $33.8 million, an 11% decrease year-over-year but a 33% increase compared to the previous quarter.
• The company's revenue backlog reached a record high of $206 million, a 17% increase year-over-year.
• Gross profit for the third quarter was $2.4 million, a significant decrease from $9.8 million in the same quarter last year.
• The company is maintaining its full fiscal year 2024 revenue guidance of $137 million to $147 million.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the poor financial results for the quarter and the need to refinance debt, although the record backlog and new facility are positive signs. The company is facing significant challenges in profitability and cash flow.

Positives

• The company secured a record high revenue backlog of $206 million, indicating strong future demand.
• The company completed its cell and gene therapy facility, significantly increasing its potential revenue capacity.
• The company's third quarter revenue increased by 33% compared to the previous quarter.
• The company is refinancing its debt, which may improve its financial stability.
• The new notes have a fixed interest rate of 7.00%.

Negatives

• Third quarter revenue decreased by 11% compared to the same period last year.
• Gross profit for the third quarter significantly decreased to $2.4 million from $9.8 million year-over-year.
• The company reported an operating loss of $4.0 million for the third quarter, compared to an operating income of $2.7 million in the same quarter last year.
• The company's cash and cash equivalents decreased to $30.7 million from $38.5 million since April 30, 2023.
• The 2026 notes were accelerated and became due on February 29, 2024, indicating potential financial strain.

Risks

• The offering is subject to market conditions and may not be completed as planned.
• The company's stock price could be negatively impacted by the unwinding of capped call transactions related to the 2026 notes.
• The company may experience delays in engaging new customers or converting its backlog into revenue.
• The company's new cell and gene therapy business may not become profitable for several years.
• The company's financial results may differ from the preliminary results due to financial close and review procedures.

Future Outlook

The company expects a significant portion of its record backlog to be recognized as revenue over the next five fiscal quarters and maintains its full fiscal year 2024 revenue guidance of $137 million to $147 million.

Industry Context

The announcement reflects a common strategy in the biotech industry where companies use convertible debt to manage their capital structure and fund operations, particularly when facing near-term debt maturities. The company's focus on expanding its manufacturing capabilities aligns with the growing demand for biologics and cell and gene therapy manufacturing services.

Comparison to Industry Standards

• The decrease in Avid's gross margin is concerning, as it falls below the industry average for CDMOs, which typically aim for gross margins above 30%.
• Companies like Lonza and Catalent, which are larger CDMOs, generally maintain higher gross margins due to economies of scale and more diversified service offerings.
• The increase in Avid's backlog is a positive sign, but the company needs to improve its operational efficiency to convert this backlog into revenue and profit.
• The company's move to refinance its debt is similar to actions taken by other biotech companies facing debt maturities, but the success of this strategy will depend on the company's ability to improve its financial performance.

Stakeholder Impact

• Shareholders may experience short-term volatility due to the debt offering and potential stock dilution.
• Employees may be impacted by the company's financial performance and any potential restructuring.
• Customers may benefit from the company's increased capacity and service offerings.
• Creditors may be impacted by the company's debt refinancing and financial performance.
• Suppliers may be impacted by the company's financial performance and any potential changes in demand.

Next Steps

• The company will close the convertible note offering on or around March 12, 2024.
• The company will use the proceeds to repurchase and repay its 2026 notes.
• The company will continue to execute on its backlog and work to improve its financial performance.

Key Dates

Keywords

Convertible Notes, Private Placement, Debt Refinancing, CDMO, Biologics, Revenue Backlog, Financial Results, Cell and Gene Therapy, Manufacturing, Senior Notes